Huang M N, Takita H, Douglass H O
J Surg Oncol. 1978;10(2):179-82. doi: 10.1002/jso.2930100210.
Osteogenic sarcoma, excluding the paraosteal osteosarcoma, has a grave prognosis, half of the patients dying within 1 year following ablative surgery of the primary lesion. Once pulmonary metastasis is detected, most patients do not survive more than 3 years. Various attempts by investigators to prolong patient survival, including surgery, chemotherapy, immunotherapy, radiation therapy, and combined modalities, have met with some success. This report is a summary of 13 patients who underwent lung resections and received adjuvant chemo- and/or immunotherapy for metastatic osteogenic sarcoma in our intstitute in the past 7 years.
骨肉瘤(不包括骨旁骨肉瘤)预后严重,一半患者在原发灶切除术后1年内死亡。一旦发现肺转移,大多数患者存活不超过3年。研究人员为延长患者生存期进行了各种尝试,包括手术、化疗、免疫治疗、放射治疗以及联合治疗,均取得了一定成效。本报告总结了过去7年在我院接受肺切除术并接受辅助化疗和/或免疫治疗的13例转移性骨肉瘤患者的情况。